Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

Blood

Volumn 113, Issue 23, 2009, Pages 5720-5726

  DiPersio, John F ^a   Stadtmauer, Edward A ^b   Nademanee, Auayporn ^c   Micallef, Ivana N M ^d   Stiff, Patrick J ^e   Kaufman, Jonathan L ^f   Maziarz, Richard T ^g   Hosing, Chitra ^h   Früehauf, Stefan ⁱ   Horwitz, Mitchell ^j   Cooper, Dennis ^k   Bridger, Gary ^l   Calandra, Gary ^l  

^a USA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f EMORY UNIVERSITY   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l GENZYME CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; PLERIXAFOR; HETEROCYCLIC COMPOUND;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; CD34 SELECTION; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEMATOPOIETIC STEM CELL; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL MOBILIZATION; SURVIVAL; TREATMENT OUTCOME; VOMITING; ADOLESCENT; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; PHASE 3 CLINICAL TRIAL;

ADOLESCENT; ADULT; AGED; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS;

EID: 67651089936     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-174946     Document Type: Article

References (40)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335: 91-97. (Pubitemid 26240110)
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348:1875-1883. (Pubitemid 36532313)
3. Fermand J-P, Katsahian S, Divine M, et al. Highdose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227-9233. (Pubitemid 46260178)
4. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65. (Pubitemid 29019388)
5. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349:2495-2502. (Pubitemid 38010075)
6. Barlogie B, Tricot GJ, van Rhee F, et al. Longterm outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006;135:158-164. (Pubitemid 44401612)
7. Demirer T, Buckner C, Gooley T, et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant. 1996;17:937-941. (Pubitemid 26235837)
8. Desikan KR, Barlogie B, Jagannath S, et al. Comparable engraftment kinetics following peripheralblood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol. 1998;16:1547-1553. (Pubitemid 28175779)
9. Perea G, Sureda A, Martino R, et al. Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol. 2001;80:592-597. (Pubitemid 33061999)
10. Boeve S, Strupeck J, Creech S, Stiff PJ. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant. 2004;33:997-1003. (Pubitemid 38744785)
11. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 2002;527:255-262. (Pubitemid 35253875)
12. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201:1307-1318. (Pubitemid 40629073)
13. Rosenkilde MM, Gerlach LO, Hatse S, et al. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem. 2007; 282:27354-27365. (Pubitemid 47501954)
14. Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;1061867-1061874 (Pubitemid 41208607)
15. Meehan KR, Areman EM, Ericson SG, Matias C, Seifeldin R, Schulman K. Mobilization, collection, and processing of autologous peripheral blood stem cells: development of a clinical process with associated costs. J Hematother Stem Cell Res. 2000;9:767-771. (Pubitemid 30848412)
16. Corso A, Caberlon S, Pagnucco G, et al. Blood stem cell collections in multiple myeloma: definition of a scoring system. Bone Marrow Transplant. 2000;26:283-286. (Pubitemid 30614407)
17. Desikan KR, Tricot G, Munshi NC, et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol. 2001;112:242-247. (Pubitemid 32151178)
18. Weaver C, Birch R, Greco F, et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol. 1998;100:338-347. (Pubitemid 28131068)
19. Alegre A, Tomás J, Martínez-Chamorro C, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant. 1997;20: 211-217. (Pubitemid 27361913)
20. Koc ON, Gerson SL, Cooper BW, et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol. 2000;18:1824-1830.
21. Gupta S, Zhou P, Hassoun H, et al. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. Bone Marrow Transplant. 2005;35:441-447. (Pubitemid 40403345)
22. Dingli D, Nowakowski G, Dispenzieri A, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma. 2006;6:384-388.
23. Seggewiss R, Buss EC, Herrmann D, Goldschmidt H, Ho AD, Fruehauf S. Kinetics of peripheral blood stem cell mobilization following G-CSF-supported chemotherapy. Stem Cells. 2003;21:568-574. (Pubitemid 37444113)
24. Delamain MT, Metze K, Marques JF Jr, Reis AR, De Souza CA, Lorand-Metze I. Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF. Transfus Apher Sci. 2006;34:33-40. (Pubitemid 43220387)
25. Hicks ML, Lonial S, Langston A, et al. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion. 2007;47:629-635. (Pubitemid 46449623)
26. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2007;41:331-338.
27. Vogel W, Kopp H, Kanz L, Einsele H. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol. 2005;131:214-218. (Pubitemid 40238936)
28. Ho J, Yang L, Banihashemi B, et al. Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant. 2009;43:223-228.
29. + cells to remove circulating tumor cells. Blood. 1996;87:1625-1634.
30. + cells to support single or tandem high-dose chemotherapy. Blood. 2000; 95:2234-2239.
31. Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of AML following mobilization by the CXCR4 antagonist AMD3100. Blood. Prepublished on December 2, 2008; as DOI 10.1182/blood-2008-06-162163.
32. Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003;120:413-423. (Pubitemid 36241497)
33. Boccadoro M, Palumbo A, Bringhen S, et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica. 2002;87:846-850. (Pubitemid 34851555)
34. Ghobrial IM, Dispenzieri A, Bundy KL, et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant. 2003;32:587-592. (Pubitemid 37185094)
35. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21:2035-2042. (Pubitemid 47299979)
36. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia. 2007;22:1280-1281.
37. Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia. 2008;22:1282-1284. (Pubitemid 351833805)
38. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non- Hodgkin's lymphoma. J Clin Oncol. 2004;22: 1095-1102. (Pubitemid 41095043)
39. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 2005;45:295-300. (Pubitemid 40389423)
40. Flomenberg N, DiPersio J, Calandra G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol. 2005;114: 198-205. (Pubitemid 41567002)